Josep Tabernero

Josep Tabernero

UNVERIFIED PROFILE

Are you Josep Tabernero?   Register this Author

Register author
Josep Tabernero

Josep Tabernero

Publications by authors named "Josep Tabernero"

Are you Josep Tabernero?   Register this Author

100Publications

3014Reads

-Profile Views

Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.

Expert Opin Investig Drugs 2019 May 20;28(5):463-471. Epub 2019 Apr 20.

a Department of Medical Oncology , Vall D'Hebron University Hospital Barcelona/Universitat Autònoma de Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1599860DOI Listing
May 2019

Shortages of inexpensive essential medicines.

Lancet Oncol 2019 May 18;20(5):e224-e225. Epub 2019 Apr 18.

ESMO President, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30248-7DOI Listing
May 2019

ESMO-MCBS: setting the record straight.

Lancet Oncol 2019 Apr;20(4):e192

European Society for Medical Oncology-Magnitude of Clinical Benefit Scale Working Group, Lugano, Switzerland; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30174-3DOI Listing
April 2019

New clinical trial designs in the era of precision medicine.

Mol Oncol 2019 Mar 22;13(3):549-557. Epub 2019 Feb 22.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396357PMC
March 2019

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.

ESMO Open 2019 6;4(2):e000460. Epub 2019 Mar 6.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435239PMC
March 2019

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations.

Authors:
Josep Tabernero

ESMO Open 2019 31;4(1):e000494. Epub 2019 Jan 31.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435243PMC
January 2019

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.

Br J Cancer 2018 Nov 15;119(10):1208-1214. Epub 2018 Oct 15.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0246-z
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0246-zDOI Listing
November 2018

All change: closing the gender gap in oncology.

Authors:
Josep Tabernero

ESMO Open 2018 15;3(7):e000448. Epub 2018 Nov 15.

ESMO President 2018-2019, Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2018-000
Publisher Site
http://dx.doi.org/10.1136/esmoopen-2018-000448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242021PMC
November 2018

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

J Natl Cancer Inst 2018 Oct;110(10):1142-1143

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy029DOI Listing
October 2018

Biosimilars in oncology.

Authors:
Josep Tabernero

ESMO Open 2018 24;3(6):e000456. Epub 2018 Oct 24.

Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215690PMC
October 2018

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Clin Colorectal Cancer 2018 09 8;17(3):170-178.e3. Epub 2018 Mar 8.

Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, Edegem, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.03.005DOI Listing
September 2018

The safety of ramucirumab for the treatment of colorectal cancer.

Expert Opin Drug Saf 2018 Sep 16;17(9):945-951. Epub 2018 Aug 16.

c Department of Medical Oncology , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2018.1506762DOI Listing
September 2018

Preparing for the incoming wave of biosimilars in oncology.

ESMO Open 2018 5;3(6):e000420. Epub 2018 Sep 5.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144900PMC
September 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 May 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:231-238

From the Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Catalan Institute of Oncology, Oncobell Program, L'Hospitalet de Llobregat, CIBERONC, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200929
Publisher Site
http://dx.doi.org/10.1200/EDBK_200929DOI Listing
May 2018

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J Clin Oncol 2018 Mar 17;36(9):850-858. Epub 2018 Jan 17.

F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA; Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London, London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.1644DOI Listing
March 2018

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Genome Med 2018 03 28;10(1):25. Epub 2018 Mar 28.

Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical, Research Institute and Pompeu Fabra University, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-018-0531-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875005PMC
March 2018

Reply to M. Mo et al.

J Clin Oncol 2018 Jan 21;36(3):303. Epub 2017 Nov 21.

Manish A. Shah, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Luis A. Herráaez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Amit Garg, Genentech, South San Francisco, CA; and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2758DOI Listing
January 2018

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

Am Soc Clin Oncol Educ Book 2017 ;37:210-215

From the Early Drug Development Unit, Vall d'Hebron University Hospital and Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EDBK_180460DOI Listing
December 2017

The Cancer Moonshot from a European perspective.

Lancet Oncol 2017 11 31;18(11):e626. Epub 2017 Oct 31.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autànoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30798-2DOI Listing
November 2017

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Nat Rev Clin Oncol 2017 09 4;14(9):562-576. Epub 2017 Apr 4.

Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.40DOI Listing
September 2017

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.

J Clin Oncol 2017 Aug 2;35(22):2558-2567. Epub 2017 Jun 2.

Manish A. Shah, Meyer Cancer Center, Meyer Cancer Center at Weill Cornell Medical College, Medical Oncology/Solid Tumor Program, New York, NY; Amit Garg and Mona Shing, Genentech, South San Francisco, CA; Rui-hua Xu, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou; Tianshu Liu, Zhongshan Hospital of Fudan University; Fan Xia, Roche (China) Holding, Ltd, Shanghai, People's Republic of China; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Paulo M. Hoff, Hospital Sírio Libanês, São Paulo, Brazil; Luis A. Herráez-Baranda, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Josep Tabernero, Vall d'Hebron University Hospital and and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6852DOI Listing
August 2017

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis.

Pancreas 2017 08;46(7):913-920

From the *Pathology, †Oncology, ‡Surgery, and §Radiology Departments, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000000867DOI Listing
August 2017

Cancer: A precision approach to tumour treatment.

Nature 2017 08 19;548(7665):40-41. Epub 2017 Jul 19.

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature23101DOI Listing
August 2017

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.

Cancer Discov 2017 07;7(7):666-669

Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-17-0500DOI Listing
July 2017

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

Eur J Cancer 2017 06 13;78:61-69. Epub 2017 Apr 13.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.03.007DOI Listing
June 2017

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

J Natl Cancer Inst 2017 05 31;109(5). Epub 2016 Dec 31.

Affiliations of authors: Department of Gastroenterology and GI Oncology, Université Paris Descartes, Hopital Européen Georges Pompidou, Paris, France (JTai); Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France (KLM); Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (QS, DJS); Department of Pathology, Centre Jean Perrin, EA ERTICa, Université d'Auvergne, Clermont-Ferrand, France (FPL); Centre Hospitalier Universitaire Robert Debré, Reims, France (OB); Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain (JTab); Spanish Gastrointestinal Tumors TTD Group, Universitat Autònoma de Barcelona, Barcelona, Spain (JTab); Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy (EM); Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG); First Medical Department, University Hospital Carl Gustav Carus, Dresden, Germany (GF); Department of Gastroenterology, Hôpital Universitaire Erasme, Brussels, Belgium (JLVL); Department of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN (SRA, FAS); Pathology Department, Ambroise Paré Hospital, Boulogne, France (JFE); Université Paris Descartes, Sorbonne Paris Cité, France (PLP); Assistance Publique Hôpitaux de Paris, Department of Biology, Hôpital Européen Georges Pompidou, Paris, France (PLP); INSERM UMR-S1147, Paris, France (PLP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075212PMC
May 2017

The expanding role of immunotherapy.

Cancer Treat Rev 2017 Mar 11;54:74-86. Epub 2017 Feb 11.

Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.01.008DOI Listing
March 2017

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Nat Rev Cancer 2017 02 4;17(2):79-92. Epub 2017 Jan 4.

Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.126DOI Listing
February 2017

Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.

Expert Opin Emerg Drugs 2016 Sep 12;21(3):267-82. Epub 2016 Aug 12.

a Spain - Medical Oncology Department , Vall d'Hebron University Hospital , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1220535DOI Listing
September 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016